Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.195
-0.025 (-0.78%)
At close: Jan 16, 2026, 4:00 PM EST
3.190
-0.005 (-0.16%)
After-hours: Jan 16, 2026, 4:04 PM EST
Anixa Biosciences Employees
As of October 31, 2024, Anixa Biosciences had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,185,400
Market Cap
106.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 5 | 0 | - |
| Oct 31, 2023 | 5 | 0 | - |
| Oct 31, 2022 | 5 | 0 | - |
| Oct 31, 2021 | 5 | 1 | 25.00% |
| Oct 31, 2020 | 4 | -4 | -50.00% |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANIX News
- 4 weeks ago - Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - PRNewsWire
- 5 weeks ago - Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - PRNewsWire
- 5 weeks ago - Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - PRNewsWire
- 2 months ago - Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript - Seeking Alpha
- 2 months ago - Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization - PRNewsWire
- 2 months ago - Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat - GlobeNewsWire
- 2 months ago - Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s - PRNewsWire
- 2 months ago - Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 - PRNewsWire